Next Article in Journal
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
Next Article in Special Issue
Immunotherapy in Glioblastoma: Current Shortcomings and Future Perspectives
Previous Article in Journal
Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses
Previous Article in Special Issue
A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia
 
 
Article

Article Versions Notes

Cancers 2020, 12(2), 474; https://doi.org/10.3390/cancers12020474
Action Date Notes Link
article xml file uploaded 18 February 2020 14:06 CET Original file -
article pdf uploaded. 18 February 2020 14:06 CET Version of Record https://www.mdpi.com/2072-6694/12/2/474/pdf-vor
article supplementary file uploaded. 18 February 2020 14:06 CET - https://www.mdpi.com/2072-6694/12/2/474#supplementary
article xml file uploaded 21 February 2020 11:54 CET Update -
article xml uploaded. 21 February 2020 11:54 CET Update https://www.mdpi.com/2072-6694/12/2/474/xml
article pdf uploaded. 21 February 2020 11:54 CET Updated version of record https://www.mdpi.com/2072-6694/12/2/474/pdf
article html file updated 21 February 2020 11:58 CET Original file -
article html file updated 7 March 2020 12:06 CET Update -
article html file updated 7 March 2020 14:53 CET Update -
article html file updated 20 July 2022 20:31 CEST Update https://www.mdpi.com/2072-6694/12/2/474/html
Back to TopTop